Centrus Energy Corp. (LEU) Earnings Call Transcript
November 5, 2026
Earnings Call Speaker Segments
Hello, everyone, and welcome. We're glad to have you with us by phone and on the webcast. Today we'll go over the third-quarter 2026 results, which ended September 30th. With us are Amir Vexler, our President and Chief Executive Officer, and Todd Tinelli, Senior Vice President, Chief Financial Officer and Treasurer. This call comes after the earnings news release we put out yesterday. This morning, we filed our Form 10-Q quarterly report for the third quarter. You can find all our news releases and SEC filings — our 10-K, 10-Qs, and 8-Ks included — on our website. A recording of today's session will be posted on the Centrus website later this morning. Everyone should be aware that certain matters we may cover today might be viewed as forward-looking information carrying risks and uncertainty, including assumptions about Centrus's future performance. Our actual results could differ materially from those in our forward-looking statements. Further details on factors that might cause actual results to differ materially from those in our forward-looking statements appears in our SEC filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. The forward-looking information given today is time-sensitive and accurate only as of today, November 5th, 2026, unless otherwise noted. I want to point out that our results are presented using non-GAAP financial measures. We think these give investors a fuller picture of how the company is performing financially, and they also help with strategic financial planning, analysis, and comparing one period to another. You can find a reconciliation to the closest comparable GAAP figures in the financial results section of our earnings release. This call belongs to Centrus Energy. No one may transcribe, redistribute, retransmit, or rebroadcast it in any form without Centrus's express written consent. Thanks for joining us. I'll hand things over now to Amir. Amir?
Thanks, Neil, and I appreciate all of you joining us today. It's a pleasure to report that Centrus continues to build on its reputation for keeping its commitments, and as that credibility expands, we're winning a bigger portion of the market. In the third quarter we achieved significant progress on our commercial, operational, and financial objectives, and the crowning moment came with our recent accomplishment of completing the first centrifuge at Oak Ridge, Tennessee — earlier than the year-end goal. We've now proven that building centrifuges in the US is something real; that represents a historic milestone both for Centrus and for the United States. This landmark moment resulted from a series of other team accomplishments, among them the strategic purchase of Westerman, one of our key suppliers. That step meant we officially locked in every supplier we consider critical, and it also came with completion of our first certified for construction packages — two more 2026 operational targets reached ahead of the year-end target. On top of that, our enrichment backlog rose from $3 billion to $5.4 billion, and we raised funds successfully in a prudent way that leaves us well capitalized. Finally, we’re pleased to report that we are now producing enriched HALEU for the commercial market through the 16-centrifuge cascade already in place, which makes Centrus the first commercially owned US enricher serving that market since the era of gaseous diffusion. Against that background, we observe commercial validation persisting and broadening across each of the three markets we serve: commercial LEU for the current fleet of commercial nuclear reactors providing baseload electricity, a growing national security requirement that continues to diversify further, and HALEU supporting next-generation reactors, which will likewise require LEU feedstock. It is important to separate the opportunity set that is specific to Centrus from those of the broader nuclear market; we are positioned to take advantage of all three of these markets. To start, and this matters most, our number one priority is baseload power secured through agreements with investment-grade utilities. There is already a substantial and widening mismatch between commercial LEU demand and supply. Remember that a big share of our long-dated enrichment backlog extending out to 2040 consists of LEU meant for those same existing investment-grade utilities. Our second market is the expanding requirements of national security. A recent US GAO report raised concerns regarding the country's whole domestic nuclear fuel supply chain, particularly the portion of that chain able to satisfy national security demand. In particular, the report drew attention to the government's plan, worth $37 billion, to rebuild the unobligated supply chain by 2052. During last week's announcement, we verified that no obligations encumber our supply chain. Furthermore, Centrus's validated, risk-mitigated technology stands as the sole production-capable choice available to the national security community. Accordingly, we are continuing to collaborate with the NNSA regarding its plan to award a sole-source contract to Centrus for specific uranium enrichment work, and we remain prepared to assist with that critical mission. Next, consider HALEU along with the advanced reactor sector. Demand within this sector constitutes an expanding growth prospect that is still developing. We have positioned ourselves to capitalize on this prospective market should it reach maturity, which affords us extra optionality. Such optionality encompasses the ability to direct planned HALEU capacity toward assorted assays of LEU and LEU+ when necessary. A key point: we're locking in prepayments to finance our growth through the HALEU offtake deals we're signing. That said, our primary focus has been durable LEU demand from investment-grade reactor operators. We continue to observe this supply-demand gap widening, driven by uprates, mothballed facilities returning to service, and potential new builds, both in the US and abroad; this widening disparity is shown by the continually rising spot and long-term contract LEU pricing curves that remain on an upward trajectory. Let me now go into the progress we made against our three objectives. Starting with operations: last week’s gathering in Oak Ridge, Tennessee, where we marked the completion of our first centrifuge, has us extremely enthusiastic. That occasion signals the beginning of our ramp toward scaled centrifuge production. Reaching this significant milestone well before our year-end goal demonstrates that our core manufacturing operations in Oak Ridge are now fully established, and that our process has been qualified and is tested and proven. The team’s current priorities are shortening cycle times, increasing throughput rates, eliminating inefficiencies, and expanding our infrastructure together with our supply chain while recruiting and training staff. Also, we're really enthusiastic about buying Westerman recently. That deal ought to generate growth for the two companies via commercial and operational synergies, plus cost savings, while lowering the risk on our build-out. For Centrus this acquisition marks a major milestone; through a single strategic step, we've at the same time reduced build-out risk by locking in a key supplier and a best-in-class maker of centrifuge casings and other critical parts, secured cost-saving synergies connected to Westerman's expansion and to our own expansion, and reduced the risk across our whole business model in the near and medium term thanks to an established, high-quality industrial fabricator with revenue in nuclear and non-nuclear industries. Moving to commercial backlog: during the third quarter we recorded substantial expansion, lifting our enrichment backlog to $5.4 billion in contingent LEU and HALEU sales commitments. Each of our announced agreements with X-energy, Radiant, and Antares carried prepayments intended to support our build-out. In addition, the X-energy agreement provides for producing LEU as feedstock for HALEU, which helps us push more volume through our facility. Lastly, the offtake agreements with Radiant and Antares provide further validation and reinforce the first-mover advantage we hold in the microreactor market. They likewise show that we can produce unobligated enriched uranium capable of supporting US national security applications, including defense and space missions. Last, regarding pillar three—financial progress—Centrus brought in another $500 million, and as much as $2 billion more could follow down the road. Along those lines, the company closed the quarter carrying about $2.2 billion in unrestricted cash on the balance sheet. Todd will go into greater detail on that shortly. Now to guidance: for 2026, we're reaffirming full-company annual revenue guidance of $450 million to $500 million, plus capital spending of $350 million to $500 million for the year. Likewise, we're reaffirming our 2026 annual guidance calling for more than 175 new hires added to the Piketon workforce, together with our goal of at least 100 new employees at Oak Ridge. Having now secured agreements with all of the partners we regard as essential, we managed to complete and begin delivery of our initial centrifuge. Acquiring Westerman represents another significant move toward making our supply chain even stronger. In parallel, we have finished our inaugural certified for construction package for Piketon. These topics will be covered in more detail during our Investor Day this coming December. With that said, I'll pass things over to Todd and then return with a few closing thoughts and remarks. Todd?
Thanks, Amir, and good morning to everyone joining today's call. Before walking you through the results, I want to touch briefly on how our recent capital raise has affected things. During the third quarter, we booked a $46.4 million gain stemming from a decrease in the liability associated with warrant valuation from that recent capital raise. That item was noncash on our books, but it still drove a $46.4 million favorable impact on operating income, net income, and earnings per share for the quarter that sits outside our ordinary business. So whenever I refer in my remarks to operating income, net income, and earnings per share excluding that $46.4 million gain, I'll describe them as normalized, together with those same adjusted figures that reflect growth costs. Our normalized results landed in line with internal projections and reflected the typical quarter-over-quarter contractual mix shift that can arise depending on customer orders and deliveries. Solid financial execution on our side continues to support execution of our multi-billion dollar domestic enrichment expansion. As I've mentioned on prior calls, I'll present financials on both a quarterly and trailing twelve-month basis. Third quarter total revenue was $55.5 million, a decrease of $19.4 million, or 26%, versus the same period a year ago. TTM revenue came to $454.5 million, exceeding fiscal 2025 revenue. The LEU segment generated $31.8 million of revenue in the third quarter, a 29% decline compared with the same period last year. SWU revenue increased by $3.4 million in the quarter, reflecting a 19% rise in the volume of SWU sold and a 10% rise in the average SWU selling price. Technical Solutions segment revenue was $23.7 million in the third quarter, a decline of $6.4 million, or 21%, versus the same period last year, due mainly to a $10.2 million reduction in revenue from the HALEU operations contract, along with a change related to other contracts. Centrus posted a loss of $10.6 million and a gross profit of $105.8 million for the third quarter and TTM, respectively, versus a gross loss of $4.3 million in Q3 2025. Cost of sales for the LEU segment in the third quarter was $38.7 million, down $13.9 million, or 26%, from the prior-year period, driven by lower volume of uranium sold. SWU cost rose as a result of a 28% increase in the average unit cost of SWU sold and a 19% increase in the volume of SWU sold. Technical Solutions cost of sales of $27.4 million was up $0.8 million, or 3%, from Q3 2025, primarily attributable to higher cost related to customer contracts, partially offset by a $1.7 million decrease in cost incurred under the HALEU operation contract. Normalized operating loss for the third quarter was $25.1 million, compared with a loss of $16.6 million in the same period last year. On a per-share basis, that worked out to $0.19, $0.25, $0.46, and $0.49 across the respective measures we track. In Q3, the company recorded a normalized net loss of $10.2 million and an adjusted net loss of $9.4 million, compared with normalized net income of $3.9 million and adjusted net income of $5.2 million, respectively, in Q3 2025. A number of factors contributed to the swing into a normalized net loss for the quarter: a $9 million decline in income tax benefit, gross loss that rose by $6.3 million, and advanced technology costs up $3 million. Partially offsetting that change in normalized net loss was a $4 million gain in investment income. On a fully diluted basis, that translates to a third-quarter 2026 normalized loss per share of 49 cents and an adjusted loss per share of 46 cents, respectively, compared with 19 cents and 25 cents, respectively, in Q3 2025. Across the trailing twelve months, Centrus generated normalized net income of $34.4 million and adjusted net income of $77.3 million, respectively. Third-quarter adjusted net income excludes $2.4 million of growth expenses and a $1.3 million benefit to our SG&A related to our stock compensation, which combined and tax adjusted equals $800,000. For reconciliations of net income, normalized net income, and adjusted net income, please refer to the financial results section of our earnings release issued yesterday. Looking forward, we continue to expect a certain level of these growth expenses to flow through our income statement as the build-out proceeds. As of the end of the third quarter, Centrus's backlog across both segments had reached $7 billion and extends out to 2040. That increase came from roughly $2.4 billion in LEU and HALEU enrichment sales within the LEU segment. Of the approximate $5.4 billion in contingent LEU and HALEU sales commitments, $5.1 billion are under definitive agreements. Turning to capital spend, which covers capex and non-capex attributed to costs and investments such as supplier prepayments or growth costs, total capital spend in the third quarter was $134 million, with $131.6 million from capex and the remainder from non-capex growth costs. We closed the third quarter with approximately $2.2 billion in unrestricted cash without tapping our ATM. In September, we completed an underwritten public offering of Class A common stock and pre-funded warrants, together with accompanying common warrants, of approximately $500 million. That important transaction gave us access to near-term capital at a premium while positioning the company for significant future capital across four future tranches with progressively higher exercise prices, only if our share price appreciates and we keep executing against our milestones. If exercised in full, the warrants could provide roughly $2 billion of additional gross proceeds, with exercise prices ranging from approximately $227 to $363 per share. We believe this structure reflects investor confidence in Centrus's long-term value while providing additional financial flexibility. We remain confident in our existing cash balance, and we believe we are sufficiently funded to meet our near-term capital requirements. Once the quarter wrapped up, we acquired Westerman for about $116 million, funded through a combination of cash on hand and equity — namely $95 million in cash along with $21 million in equity. We expect this transaction to lower project costs for Centrus and drive greater efficiencies across our supply chain. Turning to our outlook for the remainder of 2026: as Amir noted, we are reaffirming full-year guidance that projects revenue in the $450 million to $500 million band, together with total capital spending ranging from $350 million to $500 million. Those targets exclude the Westerman acquisition. We look forward to going into greater detail on the Westerman build-out during our December Investor Day. Additionally, we are reaffirming operational guidance regarding workforce growth at Piketon and Oak Ridge. With that, I'll turn the call back over to Amir. Amir?
Thank you, Todd. The advances we achieved in the third quarter on the commercial, operational, and financial fronts make me proud. We've come a long way, and we keep reducing the risk attached to our build-out. Manufacturing and shipping of centrifuges from our Oak Ridge facility is now underway; every supplier we consider critical has been locked in at 100%, our first CFC package is complete, and our commercial enrichment backlog has grown considerably. A healthy cash balance sits on our books, giving us the means to carry out our build-out; on top of that, the Westerman transaction we recently completed has strengthened and de-risked our business profile, particularly when it comes to near-term revenues and profitability. All this progress is unfolding while our addressable market keeps expanding — a strong backdrop that supports our expansion. We're also excited to host our upcoming Investor Day on December 7th at our American Centrifuge Plant in Piketon, Ohio. At that event, we look forward to sharing more about our strategy and build-out; with that, I'll hand the call to the operator for questions. Operator?
Morning, everyone. Amir, I have a question about the first centrifuge. Producing that initial centrifuge is a major milestone both for the company and for national security. One thing that mattered a lot to us there is that these new centrifuges are unobligated. Could you update us on how things stand with the NNSA, and also address the funding and the GAO's outline?
Morning, Mark. Thanks — that's a solid question. I want to remind both you and everyone listening that one of the major strengths we offer the market, along with the technology we deliver, is the ability to maintain unobligated production that can meet national security requirements. Also, for context, back in November of 2025, the NNSA released a notice of intent to award Centrus a sole source contract covering the manufacture of specific low-enriched uranium suited for supporting the national security mission. That's essentially the background behind our requirements and our push toward keeping production unobligated. To address your question directly, our output will be unobligated, and we've been at work configuring the supply chain, collaborating with every one of our suppliers, to ensure that this gets put into place. I hope that answers it, Mark.
Yes, indeed, thanks, Amir. I figured my line had been disconnected before the next question. Appreciate it.
Hi, Esteban Arbelaez here, filling in for Mark Bianchi — appreciate the chance to ask. My question centers on the LEU backlog as it stands now. You noted that, apart from the LEU to HALEU contract, is everything else connected to the reactors already operating? The reason I ask is that I want to get a handle on what opportunity exists for new light water reactors in that regard, and 10 new large reactors are working their way through the DOE EDF loan program. So I'm wondering how we ought to think about when potential LEU backlog opportunities might arise for Centrus in that context — if enrichment RFPs for new reactors could come along fairly soon, or whether utilities tend to hold off until closer to a reactor's startup?
Morning, everyone. Let me start with some general context, and then we’ll address the particular question about the new build. We’re very excited, and obviously our priority is firm customer commitments, and the ones for LEU are typically the ones able to make those in large volumes. A big share of our backlog is LEU for operating reactors, both in the United States and overseas. As for the specific question of how to think about new reactors that haven’t been built yet, that’s really a question for them regarding when they would feel they’d need to go out and secure fuel supply. Looking at how advanced reactor developers are behaving, securing fuel comes first for them—they put it at the head of the line so their projects carry less risk. My expectation is that new builds—AP1000s or whichever other large reactor design ends up being chosen—are going to require an enormous amount of enrichment capacity too. Given today's market, with the availability picture and the lengthy timelines involved in adding enrichment capacity, my strong advice would be to place that consideration at the very start of their planning cycle as they prepare to grow. Competing for that business is definitely our plan, and we also expect it to become a significant piece of what we do.
Hello everyone, this is Peyton Drahan, covering today for Joe Osha, and I appreciate you joining to ask questions. So, I suppose, might you share a little additional detail about what enabled the quicker schedule for that first finished centrifuge, and do you see that schedule as repeatable for later units? And then I suppose a third part: which lessons are you going to draw from this initial one and bring over to Nth-of-a-kind? Thank you.
All right. Appreciate the question. On every earnings call, I've tried to stay consistent in explaining and stressing to investors just how essential it is that we build market credibility and can meet and exceed our commitments. The market gives us an incentive to beat the timelines we've advertised, so internally we're setting up those same incentives and the same expectations around hitting the timelines. To be more specific, what made that possible is that we run a process improvements team in parallel. There's an illustration I brought up earlier that I'm certain we'll discuss eventually—I expect someone will ask about the Palantir partnership and the work we're doing together. We're genuinely going after this from several angles at once, and we're making considerable headway with our supply chain, all aimed at speeding things up, cutting costs, and reducing risk. Westerman is another case of lowering risk and adding efficiency to the supply chain, and I'm sure a question will come up about that too at some point. What we took away from this is that aligning an organization's objectives, equipping people with the right tools and clear expectations, and putting genuine resources behind fast-paced enhancements delivers results—and we fully plan to put those takeaways into practice. As it happens, regarding the latter portion of your question, those are indeed the key takeaways; we're eager to share fuller updates, specifics, and illustrations at the Investor Day I mentioned previously, and I hope that addresses what you asked.
Good morning, and congratulations on the ongoing progress. Amir, I'd like to revisit the robust macro picture you mentioned during your prepared remarks. Given how strong SWU pricing looks relative to uranium going forward, are customers adjusting tails assays at all, and how much Western SWU demand might be satisfied through overfeeding in the future?
Thanks, that's a great question. Good morning. You're putting an enrichment question to an enrichment person, but it involves far more than enrichment alone. Clearly uranium pricing plays heavily into it. Every customer and every supplier tackles this on an individual basis, contract by contract. Previously, when SWU prices were low — this takes us back several years — behavior around tails assay looked different. Behavior around underfeeding versus overfeeding also looked different. Of course, that dynamic has shifted now that SWU prices have risen substantially. My expectation is that this remains simply an optimization for each contract, handled case by case, depending on how they regard their uranium supply pricing versus how they wish to optimize it versus enrichment. As a final thought, I'd add that I tend to favor enrichment having the upper hand here. What I mean is that ultimately I think you'd see the seesaw and pendulum swing toward, in a sense, leaning in favor of prioritizing enrichment capacity, simply because I don't perceive much ability to grow capacity as rapidly as the market expands; that disparity is visible today, and I believe it will take some time before it settles. I think you'll see that reflected in the tails, in overfeeding versus underfeeding. I hope that answers your question.
Hi there, good morning. Great work on how you executed this quarter. I appreciate you taking my question. I'd like to follow up on an earlier question regarding the backlog. As we consider your commercial approach, is there a preferred blend of, let's say, established utilities with LEU versus newer players, SMR, and given how the backlog is shaped — you mentioned it stretching out to 2040 — does it lean more toward the front end or the back end? I'm simply attempting to understand what that might imply for capex as you, let's say, keep growing that backlog.
Morning, Bill, and thanks for asking. Let me begin by noting that as a rule we don't break things down or split out the amounts; even so, the overwhelming majority of what's in our backlog is LEU. It serves either LEU customers or acts as feedstock for HALEU offtake down the road. Now, that's a fairly intriguing question you raised about which group we favor and which we prefer. Answering that would be risky. Let me lay out the pros and cons — clearly we want both, and we chase both. The established LEU customers bring a great deal of certainty. They bring a great deal of volume; they bring extremely, extremely firm terms for offtake, and that is exactly what we require while we expand our facilities and put capital to work; that said, I don't wish to underestimate in any way the HALEU customers, who within just the last 6 months, a year, have grown far more dedicated to the supply chain, and we see them now able to sign something like take-or-pay arrangements and contracts that are legally binding. They hold enormous promise for a company such as ours. Should any of these SMRs or microreactors expand significantly, should there be a major build-out, that will generate a considerable need for HALEU and an exponential need for LEU. Honestly, we're working to keep a finger on both triggers, and let me also remind the investors and listeners that the third leg of the stool here is national security, where we are pushing very hard. We've positioned ourselves so we can meet the needs whenever we're called upon for national security. I hope that's enough detail and that it answered your question, Bill.
Hi Amir. Since you brought it up, I'll let you either step through that opening or shut it in my face. I just wanted to probe a bit into that $300 million in possible Palantir savings, and really, how much of it reflects validated procurement or engineering changes as opposed to opportunities still being evaluated? Should any of it be viewed as something that speeds up capacity delivery?
That's a good question, Nick. As we've said before, one of our day one priorities is squeezing out as much cost savings as possible while genuinely shortening lead times and deployment times for our expansion. We aim to leverage cutting-edge technology, tools, capabilities, and people, which is exactly why this partnership exists. We did announce a savings figure, and you cited the $300 million. A substantial portion of that has contributed strongly to our ability to deliver ahead of schedule. The way I see it — and I'm quite close to the project — most of the opportunities and most of the potential savings and value we'll capture still lie ahead of us, to the point that we're actively learning what we've achieved and how we might accelerate and broaden it. Keep an eye out for further announcements and further information, and as I said in one of my earlier answers, we plan to have a far more comprehensive discussion of this at our Investor Day; that's really what such a conversation is for. I'd love to cover it there, and we're getting ready to do so. One last thing I'll add: the first centrifuge is a really strong illustration of the value-creation-based agreement and partnership we have with companies such as Palantir. I believe we've been able to capitalize on the very first milestone we set out there, and we intend to do that routinely for every other milestone ahead of us.
Hi there, and thanks for the question. David here, sitting in for John Windham. Could you tell us where things stand — or give us some sense of status — regarding the negotiations with the DOE, and also the possibility of turning your demonstration cascade into commercial offtake, plus the chance to get some of those volumes to market a bit sooner? Thanks.
Discussions are ongoing. As I usually do when answering questions, I'll provide a bit of background and the context behind my answer, for the benefit of everyone else listening. We began a demonstration program together with the DOE. They've been a tremendous supporter. Over three years now, we've worked collaboratively and really well to demonstrate our technology. It has been hugely successful, and it gave us both the impetus and the capability to grow that into commercial operations. For the 16-centrifuge demo cascade, the natural next step is to move it into commercial operations. The cascade is producing. With the Department of Energy, we're in discussions about how to amend things and how to reach a more wholesome agreement under which this keeps serving the market, along with some of the reactors now entering the market that would need some of that material.
Building on what Amir said, that centrifuge is spinning right now for commercial purposes, and under the broader agreement, both we and the DOE want to see those machines keep running across their full life cycle. We're handling that through the long-term arrangement we have with the DOE. They've granted us rights to operate those centrifuges for commercial use as things stand, and that is exactly what's happening. At this moment, we are enriching to produce HALEU for commercial needs.
Hello, and good morning. Luke Gram here, speaking on behalf of Eric. We appreciate you taking our questions. Regarding your supply chain strategy, is it right to expect that vulnerable areas will be handled through vertical integration, the way it was with Westerman, or would you characterize that as more of a one-off from a strategic standpoint? Thank you.
Your question, I believe, is aimed specifically at the vulnerable piece. What I'd say is that the Westerman deal was very much about having the chance to take risk out of our supply chain, to take risk out of the build-out, and to take risk out of the business model, and also to be in a position to capture a great many efficiencies we see in the market. On the whole, we're highly pleased with how it turned out. There are additional tools available to us that we're putting to use in establishing a supply chain that's predictable, capable, and turns out high-quality product. Our team does these things daily; they aren't always publicized, and they aren't always communicated out to the wider community, but this is the sort of work we perform every day that goes on without publicity. You brought up the word vulnerability, and this is going to be a significant project. We work with a large number of suppliers. Every supplier brings its own strengths and its own weaknesses. We're building resilience into our supply chain, and we've built it wherever we could. We rely on quality oversight, we rely on partnerships with various suppliers, and we aren't ruling anything out. What you observed with Westerman, I think, is an instance where truly a perfect alignment of all those factors came together, and it was not by chance that this deal got done.
Let me just say a few words here — in our view, Westerman is a world-class operation, particularly when it comes to the nuclear space, and they also reach across into other industries. That brings diversity to Centrus's income stream and revenue; it's immediately accretive in year one, and it truly serves as a platform for us to expand on supply chain integration, and to take out some of those vulnerabilities if we see them present themselves through either organic growth now through Westerman or through additional M&A activities. We are extremely excited about this. Let me also note that at our Investor Day, we intend to provide significantly more information around the acquisition, and we hope that everyone on the call today is able to dial in or join us, and that's where we can provide a long-term view of our vision for Westerman and our supply chain. Thank you.
Hi, good morning. I just wanted to sort of follow up regarding the centrifuge manufacturing ramp. Now that the first one is complete, I realize you can't provide exact figures, but how do you kind of expect that ramp to unfold? Will it happen over the next year? Does it ramp up quickly, or do you have a sense of how that progresses? Thank you.
Yeah. Good morning, Rob. Just so I'm sure I've got it right, when you mention the ramp, are you referring to the cadence of the centrifuges as offline, or what exactly did you have in mind?
I believe you brought up concentrating on increasing how many centrifuges we produce — just to get a bit of color on how that takes place.
As a broad backdrop once more, when we unveiled the first centrifuge, clearly the major news isn't the centrifuge as such; the news is that we now have a working, operating production line turning out centrifuges, and we truly are marking the first unit to come off that line. There's a particular cadence and rhythm we're in right now, and we are producing. At this stage, we'll likely hold back quite a bit of that detail for our Investor Day, when we can have a much fuller discussion and presentation on it. Do expect additional information and announcements to emerge about that. The key point is that we have an operating manufacturing line that is in current production.
Thanks so much, operator. Morning to you, Amir and Todd. I'm grateful for the update today, and I'm really looking forward to Investor Day. What I'd like to get a clearer picture on is commercial HALEU. You've said the 16 cascades that exist are now producing HALEU for the commercial market. Could you confirm if that's under the Oklo, X-energy, Radiant, or Antares contracts, or does another customer account for it? And on revenue and economics from that, when do you expect the first commercial HALEU revenue to appear in the P&L? Also, how should we think about margins compared with the DOE HALEU contract? Will those margins be similar, or might commercial HALEU carry meaningfully better economics? Thank you.
That's quite a few questions, and I appreciate them, Lawson. Let me try to note them all down and answer each one. On your first question about commercial HALEU and exactly who receives it, what I can tell you is that it will go to the commercial market that needs HALEU, and everyone has seen our announcements. There's nothing more detailed beyond that, but we're very much looking forward to helping the commercial HALEU market get started; these new reactors are becoming real. They need fuel, and we're the first to be out there fueling them. Being the only HALEU cascade in the Western world capable of supplying them at this moment gives us an enormous advantage, and we look forward to offering that support. Now, I believe your next question was about comparing and contrasting the margins on these contracts with the DOE. Todd, I'll hand that one to you.
Right, so there are two distinct kinds of contracts involved here. The DOE one, clearly, was a demonstration project that gave us a way to prove what we can do while also producing enrichment material that could potentially serve the start-ups of a lot of those SMRs and microreactors. On the commercial side, far more is wrapped up in the terms of commercial contracts. Naturally, we don't disclose that kind of economics, but there are all sorts of different elements, and each contract differs on who supplies the feed — whether that's LEU or whether it comes from us. Overall pricing can vary somewhat, though we're clearly confident in their capability and in the HALEU market to deliver meaningful upside and optionality for the company. We're cheering on all the SMRs and advanced reactors, and as Amir mentioned, we're very excited to be the sole commercial enricher of HALEU fuel at this point, and we stand ready to serve every need our customers have.
Hi Amir and the team, thank you for taking my questions. For me, I suppose, regarding the Westerman acquisition, could you provide any further detail on how the margins appear at the gross margin level, and what seasonality, if any, exists in their business?
Thank you. As I mentioned, we are genuinely thrilled about Westerman. I think I will hold off on responding to one of your remarks, but we see considerable upside potential in the Centrus revenue stream. Margins in this supply chain are very robust across this industry. There are two effects here. First, since they are among our bigger suppliers, this lets us reduce risk in our supply chain and achieve cost savings while broadening our revenue base. Westerman is also engaged in additional high-growth industries, as well as oil and gas. Margins differ across each of those segments. The high-growth segment is clearly experiencing strong demand, and its margins run somewhat higher. Nuclear carries a robust margin profile, and finally, oil and gas has served as a mainstream part of Westerman's operations all along. On our investment day, we will share further details, including breakdowns of their margin profile within each segment and how much revenue they contribute to Centrus in the current year and across the coming years, if that is helpful.
Hey Joe, a couple of other points I'd like to make while we're on the subject of Westerman. I said this earlier, and it truly wasn't a coincidence. This wasn't a case of, "Hey, we're in the market to buy a company. Let's pull up a list of 100 candidates." That's not what happened here. Everyone in our industry knows Westerman as one of the strong fabrication pillars, with nuclear grade fabrication capability. They do high-precision fabrication, and as Todd mentioned, they're extremely versatile. It's a great fit, and beyond what I mentioned about significantly derisking the supply chain build-out and the business model we've laid out, we're also keeping a very strong focus on future potential and what else could be done to support our build-out and the business overall. As Todd said, and I'll say it again, we're very excited about what's still to come, and hopefully we'll be able to have a much broader conversation on December 7th.
Morning. I wanted to ask about the pace at which capital is being deployed, and I was hoping you could provide us with some extra clarity on Q4 spending. Clearly, a wide range of outcomes could still fit within the full-year guide. I'm just wondering how we should think about spending into Q4, and whether you have any early thoughts on the spending trajectory into '27? Thanks.
Thanks for the question, Jeff, and good morning. Our capital spend guidance has been maintained, and obviously you can kind of back into our fourth quarter spend. The key point I want to make is that we've reached a point where capital is going to be deployed more quickly. Construction on our first package is underway. As you can see, our initial centrifuge is coming off the production line. Our supply chain is locked in, purchase orders for all our materials have been placed, and the build-out is proceeding. I should note that every one of these figures excludes Westerman. In GAAP reporting and similar contexts, an acquisition is frequently treated as capex and growth capex, but for the sake of maintaining the status quo and quarter-over-quarter continuity, Westerman has been left out of those numbers. With that said, we plan to offer additional guidance during our Investment Day on December 7th. On the 2027 question: earlier this year, on our prior calls, I noted that we'd reach a stage where capital deployment would settle into a real cadence, and that ramp-up is happening now. The floor contract didn't begin until midyear, when we signed it, so with that starting to bear fruit and with people on the ground, our spending rises, on top of the manufacturing side. Stay tuned—we'll share more guidance on 2027. Clearly, we intend to give a fuller number in upcoming discussions.
Q (): Hi there, good morning, everyone. Thank you for that question. As we move toward the next Congress, do you anticipate any shift in the outlook regarding federal backing for domestic enrichment, or would you say that backing is mostly shielded from political cycles? Thanks.
That's a timely and fitting question. I'll say this with strong conviction: this should not alter the momentum of our industry; it should not alter the momentum behind investment, interest, attention, and the backing the US government gives to the fuel cycle and in particular to enrichment. The reason I say that is we have by now gone through the cycle of two administrations, at least in my tenure, and I have not witnessed any shift in backing, attention, or commitment. What I have witnessed is growth in it. Some of the discussions about the need for more clean energy—none of that disappears. It remains. The discussions about reindustrialization and creating jobs become even more significant at this point. So to answer your question, I truly do not see any shift. I see a need for even more robust backing and attention, and we look forward to collaborating with the new Congress on this as well.
Hello, Drew Scott here, filling in for Sean. Thanks for taking my question. Given that the first centrifuge is ahead of schedule and backlog growth is tracking well, are you seeing HALEU demand pull forward ahead of expectations at all, or do you have enough visibility to say you'd consider pulling forward capacity even further?
My apologies, I didn't catch the last part of that. Would you mind repeating the question?
Yeah. So are you observing HALEU demand being pulled forward somewhat sooner than you'd anticipated, and would that even lead you to bring capacity forward sooner than what you'd initially planned?
Yeah. Thanks for that question. I'm not really seeing reactor developers pulling demand ahead much at all. What we are seeing — and I brought this up earlier — is much stronger commitments and a far more aggressive push toward actually getting agreements locked in and taking the risk out of the fuel supply side of things for their build-out. No, there really aren't any changes to the cadence we have planned for rolling out our capacity. As I'll say once more, we are clearly hunting for every chance we get to shorten lead times and create efficiencies, and we will follow through on that. On the customer side, we aren't seeing that yet.
Hey there, good morning, everyone. I appreciate you taking my questions. My first question is about the 4Q outlook. If you look at the annual guidance, it basically implies fourth-quarter revenues of $142 to $192 million. Are there any puts and takes around that? The second part of my question is on SWU pricing versus SWU cost management. How are you thinking about that? Should we be expecting another quarter of negative gross margin this quarter?
Thanks for your question, and good morning. Yes, as you correctly said, we kept our guidance unchanged. We're optimistic, and we clearly feel that the fourth quarter gives us a full year of visibility into our strong results. As we've consistently pointed out, we see meaningful seasonality, both in when sales are actually delivered and in when we receive our shipments. That quarter-over-quarter mix creates some fluctuation in our gross margin profile. That's the reason we've been talking about this on a TTM basis, to offer a more normalized view. Regarding the negative gross margin and all of that, there's a lot of timing around when product arrives and mismatches between when we receive product and when we deliver it. So we're very confident in our full-year view, which is why we have maintained our guidance. We believe the revenue and guidance we've provided is also ex any Westerman upside — I just want to make that note. We'll be giving updated guidance at our December 7th Investor Day.
Hi everyone, appreciate you taking the question. Perhaps just a brief one regarding the backlog increase here. Did that come entirely from the three advanced reactor customers announced recently, or were there additional undisclosed customers included?
We don't disclose that, but what I can say is that it was a combination of both LEU and HALEU. Unfortunately, I'm unable to give the details. We don't provide the breakdown or separate the amounts. The overwhelming majority of the backlog is LEU, whether for LEU customers or as feedstock for our future HALEU offtakers. I hope that answers your question, Ryan.
Thanks, operator. And thanks to everyone who joined today's call; we're really excited about the Investor Day we have coming up on December 7th in Piketon, Ohio, and we're looking forward to giving the market more details at that time. Thank you.
Everyone, that brings today’s conference call to an end. We appreciate all of you taking part, and at this point you’re welcome to disconnect. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Centrus Energy Corp. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Centrus Energy Corp. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.